Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have been tested in the neoadjuvant setting for the treatment of locoregionally advanced head and neck squamous cell carcinoma (HNSCC); however, response rates are modest. We hypothesized that adding stereotactic body rad...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Leidner, Rom, Crittenden, Marka, Young, Kristina, Xiao, Hong, Wu, Yaping, Couey, Marcus A, Patel, Ashish A, Cheng, Allen C, Watters, Amber L, Bifulco, Carlo, Morris, George, Rushforth, Lessli, Nemeth, Shorin, Urba, Walter J, Gough, Michael, Bell, R Bryan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2021
Pynciau:
Clinical/Translational Cancer Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108690/
https://ncbi.nlm.nih.gov/pubmed/33963014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002485
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg